AntiCPD-1 therapy provides improved medical outcomes in advanced melanoma, but most
AntiCPD-1 therapy provides improved medical outcomes in advanced melanoma, but most sufferers experience intrinsic resistance. a short PFS 15 a few months demonstrated significant PPS improvement (= 0.036). Two sufferers experienced subsequent replies to antiCPD-1 resumption. To conclude, acquired level of resistance to antiCPD-1 was often associated with exceptional clinical outcomes and frequently provided as … [Read more…]